BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Bioinformatics Software | QIAGEN Digital Insights - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Bioinformatics Software | QIAGEN Digital Insights
X-ORIGINAL-URL:https://staging.digitalinsights.supremeclients.com
X-WR-CALDESC:Events for Bioinformatics Software | QIAGEN Digital Insights
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Halifax
BEGIN:DAYLIGHT
TZOFFSETFROM:-0400
TZOFFSETTO:-0300
TZNAME:ADT
DTSTART:20230312T060000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0300
TZOFFSETTO:-0400
TZNAME:AST
DTSTART:20231105T050000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0400
TZOFFSETTO:-0300
TZNAME:ADT
DTSTART:20240310T060000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0300
TZOFFSETTO:-0400
TZNAME:AST
DTSTART:20241103T050000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0400
TZOFFSETTO:-0300
TZNAME:ADT
DTSTART:20250309T060000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0300
TZOFFSETTO:-0400
TZNAME:AST
DTSTART:20251102T050000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Halifax:20240613T130000
DTEND;TZID=America/Halifax:20240613T140000
DTSTAMP:20260611T052242
CREATED:20240520T130441Z
LAST-MODIFIED:20241024T183044Z
UID:10000764-1718283600-1718287200@staging.digitalinsights.supremeclients.com
SUMMARY:How decentralized and small labs can adopt high-throughput NGS analysis with limited time and resource investment
DESCRIPTION:Next-generation sequencing (NGS) has rapidly gained popularity as a diagnostic testing approach due to its unparalleled ability to comprehensively analyze genetic information with high throughput and precision. However\, decentralized and small labs face significant hurdles when it comes to adopting NGS testing. From high upfront costs associated with acquiring the necessary equipment\, to the complexity of bioinformatics tools and compliance management that require specialized expertise in data analysis and data security\, adopting NGS poses challenges for labs with limited staff and infrastructure. \nTo empower small and decentralized labs to easily adopt NGS testing\, QIAGEN has launched a new secondary analysis solution for oncology and inherited disease applications that enables high-throughput secondary analysis for use with any clinical NGS data. In this webinar\, learn about QCI Secondary Analysis\, an agnostic\, cloud-based software-as-a-service (SaaS) solution that seamlessly integrates with QCI Interpret\, QIAGEN’s clinical variant interpretation and reporting software\, to deliver highly scalable and customizable Sample to Insight workflows for oncology and inherited disease applications. \nIn this webinar\, attendees will learn how QCI Secondary Analysis: \n\nStreamlines analysis from a range of assay types\, enabling labs to process more sequencing data without extensive time and resource investment.\nEnsures the highest degree of isolation and data protection\, including compliance with ISO 27001\, General Data Protect Regulation (GDPR)\, and the Health Insurance Portability and Accountability Act (HIPPA) requirements.\nDirectly connects to QCI Interpret for an integrated and automated FASTQ-to-report workflow with limited hands-on time.
URL:https://staging.digitalinsights.supremeclients.com/webinars-and-events/how-decentralized-and-small-labs-can-adopt-high-throughput-ngs-analysis-with-limited-time-and-resource-investment/
LOCATION:Virtual Global Event (Times shown in EST)
CATEGORIES:Clinical,Webinar
ATTACH;FMTTYPE=image/jpeg:https://staging.digitalinsights.supremeclients.com/wp-content/uploads/2024/08/S_1306_4_QDI_QCI_SecondaryAnalysis_Gi841410132-5.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Halifax:20240613T130000
DTEND;TZID=America/Halifax:20240613T140000
DTSTAMP:20260611T052242
CREATED:20240523T052050Z
LAST-MODIFIED:20241024T183044Z
UID:10000765-1718283600-1718287200@staging.digitalinsights.supremeclients.com
SUMMARY:Accelerating Drug Discovery with Comprehensive Curated Knowledge
DESCRIPTION:In the rapidly evolving landscape of drug discovery\, the ability to integrate high-quality research findings into knowledge graphs is paramount. For over twenty years\, the Ingenuity team with QIAGEN has curated these nodes and relationships. Our QIAGEN Biomedical KB-HD make these data available for consumption outside of Ingenuity Pathway Analysis. \nIn this talk\, we will: \n• Explore how to query and leverage this curated data resource to accelerate the drug discovery process.\n• Provide live demonstration of the underlying database Biomedical-HD\n• Show how the Biomedical KB-HD can be rapidly deployed\n• Show how the underlying schema and ontologies could serve as a scaffold for integrating your own research \nOverall\, this demonstration will show the critical role of knowledge graphs in predicting adverse outcomes and toxicity\, highlighting their transformative potential in steering pharmaceutical research and development. \nLearn more about Biomedical KB: https://qiagen.showpad.com/share/GmpIJaN5kRfsHRD5WPwgc
URL:https://staging.digitalinsights.supremeclients.com/webinars-and-events/accelerating-drug-discovery-with-comprehensive-curated-knowledge/
LOCATION:Virtual - Americas - EST\, United States
CATEGORIES:Discovery,Webinar
ATTACH;FMTTYPE=image/jpeg:https://staging.digitalinsights.supremeclients.com/wp-content/uploads/2024/05/S_1212_9_QDI_QDI_BKB_Original_61828_16x9_62947_Large-1200px.jpg
END:VEVENT
END:VCALENDAR